Stem Cell Therapies in Parkinson’s Disease: Are We Moving Too Fast?

psaffie
Sat, 28 Mar 2026 16:32:45 +0000
Data Sharing and Publications

This week, two of my patients asked me about stem-cell therapy for Parkinson’s disease after hearing that Japan had approved it as a promising treatment.

That worried me a lot. My concern is that patients may develop expectations that move ahead of the evidence. I understand that recent iPSC-based work from Japan is technically sophisticated, and early results have been encouraging. But the move toward conditional, limited approval has also raised concerns given the very small clinical evidence base.

We have been here before. Earlier fetal graft studies also showed early improvement, yet longer follow-up revealed graft-induced dyskinesias, and later post-mortem studies found Lewy body pathology within transplanted neurons, raising the possibility of host-to-graft disease propagation.

So my question is not whether cell therapy is promising. It is whether we have sufficiently addressed the lessons of the past to justify the current pace.

For clinicians: how are you counseling patients who ask about these studies now?

For scientists : what would responsible progress look like here—longer mandated follow-up, international registries, stricter endpoints, better mechanistic data before broader access?

I would genuinely like to hear how others in the community are thinking about this.

3 posts - 3 participants

Read full topic